A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR CO-ADMINISTERED WITH RIBAVIRIN IN ADULTS WITH GENOTYPE 4 CHRONIC HEPATITIS C INFECTION AND CIRRHOSIS

被引：1

作者：

Asselah, T. ^{[1
]}

Hassanein, T. ^{[2
,3
]}

Qaqish, R. B. ^{[4
]}

Feld, J. J. ^{[5
]}

Hezode, C. ^{[6
]}

Zeuzem, S. ^{[7
]}

Ferenci, P. ^{[8
]}

Pilot-Matias, T. ^{[4
]}

Yu, Y. ^{[4
]}

Mobashery, N. ^{[4
]}

机构：

[1] Univ Paris Diderot, Ctr Rech Inflammat, Hop Beaujon, APHP,Inserm,UMR 1149, Clichy, France

[2] Southern Calif Liver Ctr, Coronado, CA USA

[3] Southern Calif Res Ctr, Coronado, CA USA

[4] AbbVie Inc, N Chicago, IL USA

[5] Univ Toronto, Toronto Ctr Liver Dis, Toronto, ON, Canada

[6] Univ Paris Est, Henri Mondor Univ Hosp, AP HP, Creteil, France

[7] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany

[8] Med Univ Vienna, Vienna, Austria

来源：

关键词：

D O I：

10.1016/S0168-8278(15)31524-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1345

引用

页码：S861 / S861

页数：1